Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Fig. 6

Scheme for the mechanisms of action of APG-2449. Created with BioRender (Toronto, Ontario, Canada). CSC, cancer stem cell; EML, echinoderm microtubule-associated protein-like; MEK-ERK, mitogen-activated protein kinase kinase-extracellular signal-regulated kinase; PI3K-AKT, phosphatidylinositol 3-kinase and protein kinase B; SHP, SH2 containing protein tyrosine phosphatase; STAT, signal transducer and activator of transcription

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us